Sign inCreate account

Report workspace tools

NCT06414616COMPLETEDanonymous

Are We Overly Concerned About Rebound Fractures? Real-World Evidence of Adherence to Denosumab Therapy and Fracture Risk Associated With Drug Withdrawal: A Cross-sectional Study

Sponsor

Source record

Trakya University

Phase

Source record

Observational

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Osteoporosis

Indication / condition

AI-normalized

Osteoporosis

Intervention

Source record

Detailed source ingestion pending.

Source & freshness

Source record

NCT ID

NCT06414616

Original source

ClinicalTrials.gov

Source last updated

May 16, 2024

Ingested at

Jun 04, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06414616

Title

Are We Overly Concerned About Rebound Fractures? Real-World Evidence of Adherence to Denosumab Therapy and Fracture Risk Associated With Drug Withdrawal: A Cross-sectional Study

Sponsor

Trakya University

Status

COMPLETED

Phase

Observational

Condition raw

Osteoporosis

Condition normalized

Osteoporosis

Modality raw

Detailed source ingestion pending

Modality normalized

monoclonal antibody

Target raw

Osteoporosis

Target normalized

Osteoporosis

Interventions

Detailed source ingestion pending

Public preview

Source record

This study investigates the adherence to Denosumab therapy and the associated fracture risk upon discontinuation, particularly during the COVID-19 pandemic. It aims to provide real-world evidence on the implications of treatment compliance and the potential rebound effect on fracture risk in osteoporosis patients.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Are We Overly Concerned About Rebound Fractures? Real-World Evidence of Adherence to Denosumab Therapy and Fracture Risk Associated With Drug Withdrawal: A Cross-sectional Study

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06414616

Status

COMPLETED

Phase

Observational

Sponsor

Trakya University

Executive brief

Investment-Ready Snapshot

This study investigates the adherence to Denosumab therapy and the associated fracture risk upon discontinuation, particularly during the COVID-19 pandemic. It aims to provide real-world evidence on the implications of treatment compliance and the potential rebound effect on fracture risk in osteoporosis patients.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 16, 2024
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06414616

Indication

Osteoporosis

Modality

monoclonal antibody

Target

Osteoporosis

Intervention

Not reported

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.